Gonadorelin: what the research shows
- By Reed Calder
- Last reviewed Nov 16, 2026
- 22 studies and official documents checked
In short
Gonadorelin is the lab-made form of GnRH (gonadotropin-releasing hormone), a 10-amino-acid hormone the hypothalamus releases in pulses to tell the pituitary gland to release LH and FSH. Those two hormones tell the testes or ovaries to make sex hormones and sperm or eggs.
Gonadorelin has worked in people when it was given in pulses, about every 90 minutes by a small pump, to men and women whose brains don’t send that signal. In four men, a steady infusion of the same total dose didn’t stimulate FSH or active LH while pulses did. In men with congenital hypogonadotropic hypogonadism, a meta-analysis of 7 studies (420 men) found the pump started sperm production 5.3 months sooner than gonadotropin injections, with no clear difference in sperm count or pregnancies. In a phase 3 trial of women with primary amenorrhea from hypogonadotropic hypogonadism, ovulation occurred in 9 of 18 women on the two higher pump doses and 0 of 10 on placebo.
The use sold today is different: injections added to testosterone therapy to keep the testicles from shrinking and protect fertility. We found no human trial of that, and the evidence for keeping sperm production during testosterone therapy is for hCG, not gonadorelin. The FDA approved two gonadorelin products, in 1982 and 1989, and both are discontinued; the only gonadorelin in its drug listings is bulk powder. The 2026 WADA list names gonadorelin among testosterone-stimulating peptides in males, prohibited at all times.
EvidenceCellAnimalHumanpump trials in men and women with hypothalamic signal deficiency; no trial of injections added to testosterone therapy
You’ll often read that gonadorelin keeps your testicles from shrinking on testosterone therapy, preserves fertility, restores your natural testosterone and works as a simple injection. This page covers what gonadorelin is, why pulses matter, what the pump trials in men and women found, what we could and couldn’t find for men on testosterone, safety, and where it stands with the FDA and in sport.
Names and forms you’ll see
| Name | What it is | Studied in people? |
|---|---|---|
| Gonadorelin, GnRH, LHRH, luteinizing hormone-releasing hormone | The natural hypothalamic hormone of 10 amino acids, made in the lab (PubChem CID 638793) | Yes: by pump, by injection and as a one-time test |
| Gonadorelin hydrochloride, gonadorelin acetate | Two salt forms. Factrel was the hydrochloride, a one-time test of the pituitary; Lutrepulse was the acetate, a pump kit for women. Both are listed as discontinued (Factrel, Drugs@FDA; Lutrepulse, Drugs@FDA) | Yes: the approved uses, and the pump trials below |
| GnRH pump, pulsatile GnRH | A small pump that gives a dose under the skin or into a vein at set intervals, about every 90 minutes in the trials below | Yes: men and women with a missing hypothalamic signal |
| Leuprolide, triptorelin, goserelin, buserelin, nafarelin, histrelin, deslorelin | GnRH agonists: different, longer-lasting drugs that switch off sex hormones when given steadily. The WADA list names them next to gonadorelin (WADA, 2026) | Not covered on this page |
| Kisspeptin | A different peptide that acts one step upstream: it makes the hypothalamus release GnRH. See kisspeptin | Covered on its own page |
| Gonadorelin for animals | Gonadorelin hydrochloride is also used in cattle breeding programs, and dose studies in dairy cows are published (Lima et al., 2026) | Not people; not covered here |
CAS numbers
A CAS number is a substance’s chemical registry number. Some “research” vials list it in place of a name. A different number usually means a different form, such as a salt, or a different substance. The number below is for gonadorelin itself; the GnRH agonists have their own.
| Form | CAS number | Registry record |
|---|---|---|
| Gonadorelin | 33515-09-2 | PubChem |
What gonadorelin is
Gonadorelin is a peptide: ten amino acids, weighing 1,182.3 g/mol (PubChem CID 638793). It is the same molecule as the GnRH the hypothalamus releases (Mayo Clinic drug information, 2026).
GnRH acts on the pituitary gland, which releases LH and FSH. LH and FSH act on the testes or ovaries, which make testosterone, estrogen, sperm and eggs (Mayo Clinic drug information, 2026).
The pattern of exposure decides the effect. In four men with idiopathic hypogonadotropic hypogonadism, 10 mcg every 2 hours as pulses raised LH and FSH, while the same total dose as a steady infusion did not raise active LH or FSH, although blood levels of the hormone were the same (Matsumoto et al., 1991). That is why the trials below use pumps, not once-a-day shots.
Gonadorelin has two approved uses: as a one-time test of how well the hypothalamus and pituitary work, and, with the pump, to cause ovulation in women whose hypothalamus doesn’t release enough GnRH (Mayo Clinic drug information, 2026).
What has been studied
In men whose brain doesn’t send the signal
| Study | Who | What was used | What it found |
|---|---|---|---|
| Matsumoto et al., 1991 | 4 men with idiopathic hypogonadotropic hypogonadism, off all hormone treatment; crossover | LHRH (gonadorelin) 5 mcg every 2 hours for a week to prime the pituitary, then 10 mcg every 2 hours, as pulses or as a steady infusion of the same total dose | Pulses raised LH and FSH. The steady infusion did not raise active (bioactive) LH or FSH. Testosterone and estradiol didn’t rise during either regimen |
| Wei et al., 2021 | Meta-analysis: 8 articles from 7 studies, 420 men with congenital hypogonadotropic hypogonadism | Pulsatile GnRH against gonadotropin therapy | GnRH went with larger testicular volume (p = 0.01) and sperm appearing 5.3 months sooner (p = 0.004). No significant difference in positive sperm detection (p = 0.08), sperm concentration (p = 0.37) or pregnancy rate (p = 0.11). Allergic reactions occurred mostly with GnRH; gynecomastia and acne with gonadotropins. The authors say high-quality randomized trials are needed |
| Zhang et al., 2019 | 28 men with no sperm and congenital hypogonadotropic hypogonadism; not randomized (10 on the pump, 18 on gonadotropins) | A pulsatile gonadorelin pump or cyclical hCG and hMG, up to 24 months | Sperm first appeared at a median of 6 months on the pump and 14 on gonadotropins (p = .01). Sperm appeared in 90% and 83.3%, not a significant difference. Skin allergic redness and hardening was common with the pump; acne and breast tenderness with gonadotropins |
| Jiang et al., 2025 | 54 adult men with congenital hypogonadotropic hypogonadism; retrospective, mean follow-up 15.9 months | A pulsatile GnRH pump | At 6, 12 and 24 months testosterone averaged 234, 361 and 381 ng/dL (48 before) and testicular volume 6.22, 8.90 and 9.73 mL (3.19 before). Of 45 men treated for over 6 months, 34 collected semen and 27 produced sperm |
| Wang et al., 2025 | 7 male infants with congenital hypogonadotropic hypogonadism; one center, no comparison group | Gonadorelin 5 mcg every 90 minutes under the skin by pump for 3 to 5 months | Penile length rose from 1.27 to 2.43 cm, and inhibin B and anti-Müllerian hormone rose. Testes descended in 6 of 13; the testes of two patients re-ascended in follow-up. No obvious adverse reactions. Long-term effects need follow-up |
EvidenceCellAnimalHumansmall trials and a meta-analysis; mostly not randomized; sperm appeared sooner but counts and pregnancies didn’t clearly differ
In women with absent periods and ovulation problems
| Study | Who | What was used | What it found |
|---|---|---|---|
| Tranoulis et al., 2018 | Meta-analysis: 35 studies (3 randomized, 32 observational), 1,002 women with hypothalamic amenorrhea | Pulsatile GnRH, under the skin or into a vein | High ovulation rates, and a trend toward high pregnancy and live-birth rates per ovulatory cycle. Under-the-skin and intravenous dosing gave similar ovulation. Ovarian hyperstimulation was rare and mild; multiple pregnancies were slightly more common than in the general population; the intravenous route was rarely linked to superficial thrombophlebitis |
| Dubourdieu et al., 2013 | 30 women with hypothalamic amenorrhea and polycystic ovary syndrome; randomized | Pulsatile GnRH or combined gonadotropins (FSH plus LH) | An adequate ovarian response in 73% and 60%. Clinical pregnancy in 46% of the pulsatile group and 0% of the gonadotropin group |
| NCT01976728 (Lutrepulse, results posted) | 39 women aged 18 to 40 with primary amenorrhea from hypogonadotropic hypogonadism; randomized, double-blind phase 3, 2014 to 2018 | Gonadorelin acetate 10, 15 or 20 mcg a pulse under the skin by pump, or placebo | Ovulation in 1 of 9 women at 10 mcg, 4 of 9 at 15 mcg and 5 of 9 at 20 mcg, against 0 of 10 on placebo; the two higher doses pooled gave 9 of 18 (Fisher exact p = 0.0120 against placebo). Clinical pregnancy in 0 of 9, 2 of 9 and 5 of 10, and none on placebo (pooled p = 0.0383). No serious adverse events in any group |
EvidenceCellAnimalHumana phase 3 trial of 39 women and a meta-analysis of 35 studies
As a one-time test
A single dose of gonadorelin is used to test the pituitary. In 232 males (127 with congenital hypogonadotropic hypogonadism, 74 with constitutional delay of puberty and 31 healthy controls), the LH response was very variable: 47% of the hypogonadism patients had peak LH levels that overlapped with the delay group, and the authors concluded the test and inhibin B lacked the specificity to tell the two apart (Mosbah et al., 2020).
EvidenceCellAnimalHumanone cohort of 232 males
In men taking testosterone: what we couldn’t find
This is the use most pages sell. We searched PubMed for gonadorelin with testosterone therapy, replacement, testicular volume, spermatogenesis, trials and men, and found no human trial of gonadorelin given to men on testosterone. The results were pump studies in men with hypogonadotropic hypogonadism, infants, veterinary work and diagnostic tests.
What the literature does support for men on testosterone is a different drug. A 2025 review says low-dose hCG given with testosterone has been shown to sustain testicular testosterone and sperm production, even with gonadotropins fully suppressed (Hochu et al., 2025). A 2025 clinician’s guide to azoospermia caused by testosterone or anabolic steroids recommends stopping the drug where possible and, for persistent cases, hCG and FSH or clomiphene-type drugs, and notes a lack of well-structured, controlled, long-term studies (Hashimi et al., 2025). A 2026 review of peptides in sexual medicine lists gonadorelin as approved once and no longer manufactured (Vasylieva et al., 2026).
EvidenceCellAnimalHumanno trial found of gonadorelin in men on testosterone; the evidence is for hCG
Other research: Down syndrome
A 2022 Science paper reported that restoring GnRH signaling cleared olfactory and cognitive defects in a Down syndrome mouse model, and that pulsatile GnRH therapy improved cognition and brain connectivity in adult patients (Manfredi-Lozano et al., 2022). A 6-month brain imaging pilot followed 8 people with Down syndrome on pulsatile GnRH against 13 healthy controls (Adamo et al., 2025). A randomized, placebo-controlled trial of 56 people, registered in Switzerland, is recruiting (NCT04390646).
EvidenceCellAnimalHumana mouse model and small pilots; a randomized trial is under way
The usual claims, checked
| Claim | Verdict | What the studies found |
|---|---|---|
| Gonadorelin keeps your testicles from shrinking on testosterone | Untested | We found no trial of gonadorelin in men taking testosterone. Testicular volume grew in men with hypogonadotropic hypogonadism on the pump, a different condition (Jiang et al., 2025; Wei et al., 2021) |
| It preserves fertility on testosterone therapy | Untested | We found no trial. The evidence for keeping sperm production during testosterone therapy is for low-dose hCG, and a 2025 guide says well-structured long-term studies are lacking (Hochu et al., 2025; Hashimi et al., 2025) |
| It restores your natural testosterone | Mixed | In men with hypogonadotropic hypogonadism the pump raised testosterone, from 48 to 381 ng/dL over 2 years in one series. We found no trial in men with a working pituitary or men on testosterone (Jiang et al., 2025) |
| A daily injection works like the pump | Untested | The trials used pulses about every 90 minutes by pump, and in 4 men a steady infusion didn’t stimulate FSH or active LH. We found no trial of once-a-day injections (Matsumoto et al., 1991; Wei et al., 2021) |
| It restores sperm production in men with hypogonadotropic hypogonadism | Supported | In this setting, yes: sperm appeared in 90% of 10 men on the pump in one study, and 27 of 45 men treated for over 6 months produced sperm in another (Zhang et al., 2019; Jiang et al., 2025) |
| It is better than hCG for fertility | Mixed | In men with hypogonadotropic hypogonadism the pump started sperm production about 5 months sooner than gonadotropins, with no clear difference in sperm count or pregnancies; the studies were mostly not randomized, and none involved men on testosterone (Wei et al., 2021; Zhang et al., 2019) |
| It induces ovulation in women with hypothalamic amenorrhea | Supported | Yes. A meta-analysis of 35 studies (1,002 women) found high ovulation rates, and a phase 3 trial found ovulation in 9 of 18 women on the higher pump doses against 0 of 10 on placebo (Tranoulis et al., 2018; NCT01976728) |
| A gonadorelin product is FDA-approved and sold today | Contradicted | No. The FDA approved Factrel in 1982 and Lutrepulse in 1989, and Drugs@FDA lists both as discontinued; the FDA’s drug-listing data show only bulk powders (Factrel; Lutrepulse; openFDA NDC) |
| Compounded or online gonadorelin is pure and tested | Untested | We found no analysis of compounded or online gonadorelin products |
| Gonadorelin has no side effects | Mixed | The pump caused skin allergic reactions in men, and the drug information lists injection-site reactions, hives, flushing and rapid heartbeat with repeated doses; the 7-infant study and the 39-woman trial reported no obvious or serious ones (Zhang et al., 2019; Wei et al., 2021; Mayo Clinic; Wang et al., 2025) |
| It restarts your testosterone after a steroid cycle | Untested | We found no trial in men after anabolic steroids. The 2025 guide to steroid-induced azoospermia recommends hCG, FSH and clomiphene-type drugs (Hashimi et al., 2025) |
| Gonadorelin is banned in sport | Supported | For male athletes, yes. The 2026 WADA list names GnRH (gonadorelin) and its agonist analogues among testosterone-stimulating peptides in males, prohibited at all times (WADA, 2026) |
Verdict key. Supported: controlled data in people, or the official record, back it. Mixed: studies disagree, or the support is small or limited to one use. Untested: we found no study in people. Contradicted: the studies or record we found show no effect or the opposite.
What the studies used
| Study | What was tested | Amount and route |
|---|---|---|
| Matsumoto et al., 1991 | Pulses against a steady infusion in men | 5 mcg every 2 hours for a week, then 10 mcg every 2 hours, as pulses or a steady infusion of the same total dose |
| Wang et al., 2025 | Male infants with hypogonadotropic hypogonadism | 5 mcg every 90 minutes under the skin by pump for 3 to 5 months |
| NCT01976728 | Ovulation in women | 10, 15 or 20 mcg a pulse under the skin by pump, against placebo |
The pump trials were run by specialists with blood tests and ultrasound. Doses and pulse intervals were set for each patient, and the pump studies in men didn’t report a single fixed schedule in their abstracts. We don’t give injection schedules from seller pages, and nothing here is a dosing recommendation.
Side effects and safety
- In the pump trials. Allergic reactions occurred mostly during GnRH therapy in men with hypogonadotropic hypogonadism, while gonadotropin injections brought more gynecomastia and acne (Wei et al., 2021). Skin allergic redness and hardening was common with the pump (Zhang et al., 2019). In the 39-woman phase 3 trial no serious adverse events were reported in any group (NCT01976728), and in 7 infants no obvious adverse reactions were found (Wang et al., 2025).
- In women. Ovarian hyperstimulation was rare and mild, multiple pregnancies were slightly more common than in the general population, and the intravenous route was rarely linked to superficial thrombophlebitis (Tranoulis et al., 2018).
- The drug information. With repeated doses it lists difficulty breathing, continuing flushing and rapid heartbeat as reasons to call a doctor at once, and hardening of the skin or hives as reasons to call soon; with single or repeated doses, itching, pain, redness or swelling at the injection site and skin rash; and, less commonly with one dose, stomach discomfort, short flushing, headache, lightheadedness and nausea (Mayo Clinic drug information, 2026).
- Conditions to avoid. The same page warns that in someone with a GnRH-secreting pituitary adenoma, gonadorelin could cause pituitary problems and sudden blindness, and that the hormone rise from multiple doses may worsen a tumor that depends on estrogen, progestin or androgen (Mayo Clinic drug information, 2026).
- Product quality. We found no analysis of compounded or online gonadorelin.
- Not known. Long-term safety, safety in men taking testosterone, and effects of once-a-day injections, since the trials used pumps. Side effects people report online aren’t covered here; they come from users, not studies.
Legal and approval status
- No marketed U.S. product. Drugs@FDA lists two gonadorelin applications and both are discontinued: Factrel (NDA018123, original approval September 30, 1982, last supplement June 2000, 0.1, 0.2 and 0.5 mg vials) and Lutrepulse (NDA019687, original approval October 10, 1989, last supplement December 1993) (Factrel; Lutrepulse). A 2026 review says gonadorelin was approved and is no longer manufactured (Vasylieva et al., 2026).
- Listings. The FDA’s drug-listing data show 10 listings naming gonadorelin: 8 bulk-ingredient powders and 2 powders labeled for human prescription compounding, with no finished drug (openFDA NDC).
- Compounding. Gonadorelin isn’t named in the FDA’s list of bulk substances nominated for compounding under section 503A, updated May 14, 2026 (FDA document). We did not research whether pharmacies may lawfully compound it, and we found no FDA warning letter about it; we did not search the warning-letter database itself.
- Not in the HHS policy. The October 2026 temporary policy covers six other peptides (Reuters, 2026).
- Other countries. We did not check how other countries regulate it.
- Sport. The World Anti-Doping Agency’s 2026 list, section S2.2.1, names chorionic gonadotrophin, LH, and gonadotrophin-releasing hormone (GnRH, gonadorelin) and its agonist analogues, and kisspeptin, as testosterone-stimulating peptides in males, prohibited at all times (WADA, 2026).
What to look for if you research it
We don’t name or link sellers. These checks come from the studies and from the FDA:
- Which setting the claim is about. The pump trials were in men and women whose brains don’t send the signal. A page that cites them for men on testosterone is borrowing results from a different condition.
- Pulses or a daily shot. The trials used a pump about every 90 minutes. A steady exposure didn’t work in the one comparison we found.
- Whose evidence it is. For keeping sperm production on testosterone, the cited evidence is for hCG. Check the study named for gonadorelin and who was in it.
- Testicle size isn’t sperm. The pump studies measured sperm directly, and sperm appeared sooner without a clear gain in sperm count or pregnancies.
- “FDA-approved.” Ask for what and when: a test and a pump kit, both discontinued.
- Competition. For men, the 2026 WADA list prohibits it at all times.
Our guide to what to look for explains what each test on a lab report proves and which routes are legal; how to read a peptide study explains how to judge the studies sellers cite.
Trials under way
One gonadorelin trial we could verify is recruiting: a GnRH pump against placebo for cognition in people with Down syndrome: see the list, with sponsor, phase, size and registry links.
What’s still unknown
- Whether gonadorelin by injection does anything for testicle size, sperm or testosterone in men on testosterone therapy; we found no trial.
- Whether once-a-day or twice-a-day injections act like pulses, since the trials used pumps.
- How gonadorelin compares with hCG in men on testosterone, and with hCG and FSH in men with hypogonadotropic hypogonadism in randomized trials.
- What is in compounded or online gonadorelin; we found no analysis.
- The result of the registered Down syndrome trial, now recruiting. The registry lists no other open gonadorelin trial we could verify.
- Long-term safety of repeated pulses over years.
Retracted and flagged studies
A retracted study has been pulled by its journal, usually for serious errors or misconduct, and its results shouldn’t be relied on. A withdrawn paper was pulled, often before final publication. An expression of concern means the journal has flagged a problem it is still looking into.
We check every study this page cites against PubMed and the Retraction Watch database, and search both for flagged studies that mention Gonadorelin. We recheck every month. Last checked Nov 16, 2026.
We found no retracted, withdrawn or flagged studies that mention Gonadorelin.
Studies this page relies on
| Study | Published in | Status |
|---|---|---|
| Matsumoto et al., 1991 | Int J Androl | No retraction or concern |
| Dubourdieu et al., 2013 | Eur J Obstet Gynecol Reprod Biol | No retraction or concern |
| Tranoulis et al., 2018 | Fertil Steril | No retraction or concern |
| Zhang et al., 2019 | Am J Mens Health | No retraction or concern |
| Wei et al., 2021 | World J Mens Health | No retraction or concern |
| Mosbah et al., 2020 | Hum Reprod | No retraction or concern |
| Manfredi-Lozano et al., 2022 | Science | No retraction or concern |
| Hashimi et al., 2025 | Asian J Androl | No retraction or concern |
| Wang et al., 2025 | Endocr Connect | No retraction or concern |
| Adamo et al., 2025 | Brain Commun | No retraction or concern |
| Jiang et al., 2025 | Transl Androl Urol | No retraction or concern |
| Hochu et al., 2025 | Transl Androl Urol | No retraction or concern |
| Lima et al., 2026 | J Dairy Sci | No retraction or concern |
| Vasylieva et al., 2026 | Sex Med Rev | No retraction or concern |
Bring your questions to other researchers
Our forum opens once 100 researchers join the waitlist. Members post studies, ask what they actually found, and answer with sources.
Questions
What is gonadorelin?
Gonadorelin is the lab-made form of GnRH, the hypothalamic hormone of 10 amino acids that tells the pituitary to release LH and FSH. It is also used in cattle breeding (Mayo Clinic drug information, 2026; Lima et al., 2026).
Is gonadorelin a peptide?
Yes. It is a peptide of 10 amino acids with a molecular weight of 1,182.3 g/mol (PubChem CID 638793).
What does gonadorelin do?
It makes the pituitary release LH and FSH, which tell the testes or ovaries to make sex hormones and sperm or eggs. It works in pulses: in four men pulses raised LH and FSH and a steady infusion of the same dose did not (Mayo Clinic drug information, 2026; Matsumoto et al., 1991).
Is gonadorelin FDA-approved?
The FDA approved Factrel in 1982 and Lutrepulse in 1989, and Drugs@FDA lists both as discontinued. The FDA’s drug listings show only bulk powders (Factrel; Lutrepulse; openFDA NDC).
Does gonadorelin increase testosterone?
In men with hypogonadotropic hypogonadism, a pump raised testosterone from an average of 48 to 381 ng/dL over 2 years in one series. We found no trial in men with a working pituitary or men on testosterone (Jiang et al., 2025).
Can gonadorelin prevent testicular shrinkage on TRT?
We found no human trial of gonadorelin added to testosterone therapy. The evidence for keeping testicular function and sperm production during therapy is for low-dose hCG (Hochu et al., 2025).
Is gonadorelin better than hCG?
In men with hypogonadotropic hypogonadism the pump started sperm production about 5 months sooner than gonadotropins, but sperm count and pregnancy rates didn’t clearly differ, and none of the men were on testosterone therapy in the trials we found (Wei et al., 2021; Zhang et al., 2019).
What is the difference between gonadorelin and kisspeptin?
Kisspeptin acts one step upstream: it makes the hypothalamus release GnRH, while gonadorelin is GnRH itself. See what the research shows on kisspeptin (Mayo Clinic drug information, 2026).
Does gonadorelin work as a daily injection?
We found no trial of once-a-day injections. The trials used a pump about every 90 minutes, and a steady infusion of the same total dose didn’t stimulate FSH or active LH in four men (Matsumoto et al., 1991).
What are the side effects of gonadorelin?
Skin allergic reactions were common with the pump in men, and the drug information lists injection-site pain, redness or swelling, rash and hives, and with repeated doses flushing and rapid heartbeat (Zhang et al., 2019; Mayo Clinic drug information, 2026).
What is a GnRH pump?
A small pump that gives GnRH (gonadorelin) under the skin or into a vein at set intervals, about every 90 minutes in the trials. It has been used to induce ovulation in women and sperm production in men with hypogonadotropic hypogonadism (Tranoulis et al., 2018; Wei et al., 2021).
Is gonadorelin banned in sports?
For male athletes, yes. The 2026 WADA list names GnRH (gonadorelin) and its agonist analogues among testosterone-stimulating peptides in males, prohibited at all times (WADA, 2026).
Are there gonadorelin clinical trials recruiting?
We found one we could verify: a randomized, placebo-controlled trial of a pulsatile GnRH pump on cognition in 56 people with Down syndrome, run in Switzerland (NCT04390646). See the recruiting list.
Sources
- Matsumoto AM, et al. The physiological significance of pulsatile LHRH secretion in man: gonadotrophin responses to physiological doses of pulsatile versus continuous LHRH administration. Int J Androl. 1991;14(1):23-34. PubMed 1901051
- Wei C, et al. Spermatogenesis of Male Patients with Congenital Hypogonadotropic Hypogonadism Receiving Pulsatile Gonadotropin-Releasing Hormone Therapy Versus Gonadotropin Therapy: A Systematic Review and Meta-Analysis. World J Mens Health. 2021;39(2):265-277. PubMed 32777865
- Zhang L, et al. The Pulsatile Gonadorelin Pump Induces Earlier Spermatogenesis Than Cyclical Gonadotropin Therapy in Congenital Hypogonadotropic Hypogonadism Men. Am J Mens Health. 2019;13(1):1557988319828257. PubMed 30569789
- Jiang H, et al. Therapeutic effects of a pulsatile GnRH pump on adult male patients with congenital hypogonadotropic hypogonadism (CHH): a retrospective study. Transl Androl Urol. 2025;14(7):1920-1930. PubMed 40800099
- Wang X, et al. Efficacy and safety of pulsatile GnRH pump therapy in male infants with congenital hypogonadotropic hypogonadism. Endocr Connect. 2025;14(5):e240655. PubMed 40099791
- Tranoulis A, et al. Efficacy and safety of pulsatile gonadotropin-releasing hormone therapy among patients with idiopathic and functional hypothalamic amenorrhea: a systematic review of the literature and a meta-analysis. Fertil Steril. 2018;109(4):707-714. PubMed 29605411
- Dubourdieu S, et al. Prospective, randomized comparison between pulsatile GnRH therapy and combined gonadotropin (FSH+LH) treatment for ovulation induction in women with hypothalamic amenorrhea and underlying polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2013;168(1):54-9. PubMed 23298894
- Mosbah H, et al. GnRH stimulation testing and serum inhibin B in males: insufficient specificity for discriminating between congenital hypogonadotropic hypogonadism from constitutional delay of growth and puberty. Hum Reprod. 2020;35(9):2161-2171. PubMed 32862222
- Hochu G, et al. Preserving spermatogenesis in testosterone deficiency: innovations in replacement and stimulatory therapies. Transl Androl Urol. 2025;14(12):3975-3987. PubMed 41522318
- Hashimi MA, et al. Clinician's guide to the management of azoospermia induced by exogenous testosterone or anabolic-androgenic steroids. Asian J Androl. 2025;27(3):330-341. PubMed 39820213
- Vasylieva V, et al. Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review. Sex Med Rev. 2026;14(4):qeag078. PubMed 42862021
- Manfredi-Lozano M, et al. GnRH replacement rescues cognition in Down syndrome. Science. 2022;377(6610):eabq4515. PubMed 36048943
- Adamo M, et al. Enduring differential patterns of neuronal loss and myelination along 6-month pulsatile gonadotropin-releasing hormone therapy in individuals with Down syndrome. Brain Commun. 2025;7(2):fcaf124. PubMed 40190351
- Lima FS, et al. Increasing gonadorelin hydrochloride dose at the first GnRH of breeding Ovsynch enhances luteinizing hormone release, ovulatory response, and pregnancy in first-service lactating dairy cows. J Dairy Sci. 2026. PubMed 41698585
- ClinicalTrials.gov. Records NCT01976728 (Lutrepulse phase 3, results posted) and NCT04390646, and the 17 records that name gonadorelin, Factrel or Lutrepulse, November 16, 2026. Search
- Mayo Clinic. Gonadorelin (intravenous route, injection route): drug information from Merative Micromedex, portions last updated November 1, 2026. Mayo Clinic page
- U.S. Food and Drug Administration. Drugs@FDA: Factrel (NDA018123) and Lutrepulse (NDA019687), both discontinued, November 16, 2026. Factrel Lutrepulse
- U.S. Food and Drug Administration. openFDA drug listings (NDC): 10 listings name gonadorelin, November 16, 2026. openFDA NDC
- U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A: categories, updated May 14, 2026 (gonadorelin not named). FDA document
- World Anti-Doping Agency. 2026 Prohibited List, section S2.2.1 (GnRH, gonadorelin and its agonist analogues, in males); text checked in a national copy of the 2026 list because the WADA file would not download. WADA document
- Reuters. U.S. health department to allow temporary sale of some unapproved peptides. October 28, 2026. Article
- National Library of Medicine. PubChem compound record: Gonadorelin (CID 638793). PubChem
Last reviewed Nov 16, 2026. Approval and compounding status change often; we recheck this page when they do. Nothing here is medical advice; see our medical disclaimer. Found a mistake? Email editors@peptideresearchstudy.com.